Thirty years of HDAC inhibitors: 2020 insight and hindsight
It is now 30 years since the first report of a potent zinc-dependent histone deacetylase
(HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory …
(HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory …
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents
M Mottamal, S Zheng, TL Huang, G Wang - Molecules, 2015 - mdpi.com
Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from
histones and regulate expression of tumor suppressor genes. They are implicated in many …
histones and regulate expression of tumor suppressor genes. They are implicated in many …
Epigenetic protein families: a new frontier for drug discovery
Epigenetic regulation of gene expression is a dynamic and reversible process that
establishes normal cellular phenotypes but also contributes to human diseases. At the …
establishes normal cellular phenotypes but also contributes to human diseases. At the …
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
A Zhao, H Zhou, J Yang, M Li, T Niu - Signal Transduction and Targeted …, 2023 - nature.com
Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …
been rising in recent decades. The clinical and molecular features of hematologic …
Augmenting antitumor immune responses with epigenetic modifying agents
E Héninger, TEG Krueger, JM Lang - Frontiers in immunology, 2015 - frontiersin.org
Epigenetic silencing of immune-related genes is a striking feature of the cancer genome that
occurs in the process of tumorigenesis. This phenomena impacts antigen processing and …
occurs in the process of tumorigenesis. This phenomena impacts antigen processing and …
Recent progress in histone deacetylase inhibitors as anticancer agents
Histone Deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …
Drugs targeting epigenetic modifications and plausible therapeutic strategies against colorectal cancer
S Patnaik, Anupriya - Frontiers in Pharmacology, 2019 - frontiersin.org
Genetic variations along with epigenetic modifications of DNA are involved in colorectal
cancer (CRC) development and progression. CRC is the fourth leading cause of cancer …
cancer (CRC) development and progression. CRC is the fourth leading cause of cancer …
Dissecting histone deacetylase 3 in multiple disease conditions: selective inhibition as a promising therapeutic strategy
The acetylation of histone and non-histone proteins has been implicated in several disease
states. Modulation of such epigenetic modifications has therefore made histone …
states. Modulation of such epigenetic modifications has therefore made histone …
selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases
Background A link between histone deacetylases (HDAC s) and intestinal inflammation has
been established. HDAC inhibitors that target gut‐selective inflammatory pathways …
been established. HDAC inhibitors that target gut‐selective inflammatory pathways …
Epigenetics in cancer: what's the future?
MD Yanis Boumber, JPJ Issa - Oncology, 2011 - search.proquest.com
While several studies have documented the epigenetic effects of decitabine and azacitidine
in vitro and invivo,[31-33] other studies have elucidated other mechanisms. As an example …
in vitro and invivo,[31-33] other studies have elucidated other mechanisms. As an example …